{"product_id":"myriad-bcg-matrix","title":"Myriad Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSee the Bigger Picture\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eCurious where this company’s offerings actually sit—Stars, Cash Cows, Dogs, or Question Marks? This preview only scratches the surface; buy the full Myriad BCG Matrix for quadrant-by-quadrant placement, crisp data visuals, and practical moves you can apply tomorrow. Get a Word report plus an Excel summary so you can present, pivot, and prioritize with confidence. Purchase now and skip the guesswork—get strategic clarity fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMyRisk hereditary cancer panel\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMyRisk hereditary cancer panel holds a high share among oncologists and surgeons in a genetic-risk market projected at ~11% CAGR from 2024, driving strong referral flow and brand pull-through across oncology clinics. Consistent provider education and a fast 7–10 day turnaround remain critical to defend share and margins. If market growth moderates, MyRisk can mature into a dependable cash engine supported by steady clinic-driven volume.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeneSight pharmacogenomics (mental health)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGeneSight, acquired via Myriad’s 2015 purchase of Assurex Health, leads PGx in psychiatry as payers and psychiatrists lean on outcomes data; CDC found ~13% of US adults used antidepressants (2017–2018) and WHO estimates ~280M people live with depression globally. Strong brand and real-world studies drive adoption, but sustaining leadership demands ongoing trials, payer coverage wins, and expansion into PCP channels as mental-health demand rises.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTumor profiling \u0026amp; companion diagnostics partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOncology is shifting to targeted therapy; global companion diagnostics market reached about $8.2B in 2024 and NGS tumor profiling volumes rose ~15% y\/y, driving test–drug tie-ins that move durable volume. High-growth segment features sticky biopharma partnerships, requiring co-marketing, robust clinical utility data and seamless clinician reporting. Hold share now to lock long-term recurring testing revenue as targeted oncology adoption accelerates.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWomen’s health hereditary risk (e.g., breast\/ovarian)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOBGYNs and breast centers increasingly refer high-risk patients for hereditary screening; BRCA1\/2 pathogenic variants occur in ~1:400 people (1:40 in Ashkenazi Jews) with lifetime breast risk ~45–72% and ovarian 11–44%, driving guideline- and family-history–prompted uptake in 2024. Keep access simple, coverage stringent, and counseling scalable; sustained referrals will slow to cash-cow revenue as growth normalizes.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eReferral pipeline: accelerating from guideline prompts\u003c\/li\u003e\n\u003cli\u003eGenetic facts: BRCA prevalence 1:400; 1:40 Ashkenazi; high penetrance\u003c\/li\u003e\n\u003cli\u003eStrategy: simple access, tight payer coverage, scalable counseling\u003c\/li\u003e\n\u003cli\u003eLifecycle: Star → cash cow as growth cools\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntegrated ordering and results platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIntegrated ordering and results platform: a friction‑reducing digital UX captures provider habit as genetic testing adoption accelerates; high utilization increases throughput and stickiness, supporting Myriad's Star positioning. EHR integrations remain critical given \u0026gt;95% EHR adoption in US hospitals (2024 ONC), and clinician‑friendly reports amplify repeat use and referral flows. Platform network effects can cement category leadership.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDigital UX wins provider habit\u003c\/li\u003e\n\u003cli\u003eHigh utilization = higher throughput \u0026amp; stickiness\u003c\/li\u003e\n\u003cli\u003ePrioritize EHR integrations \u0026amp; clear reports\u003c\/li\u003e\n\u003cli\u003eNetwork effects reinforce category leadership\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiagnostics growth: \u003cstrong\u003e11%\u003c\/strong\u003e genetic-risk and \u003cstrong\u003e$8.2B\u003c\/strong\u003e CDx\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMyRisk: high provider share in a genetic-risk market growing ~11% CAGR from 2024; 7–10 day TAT and provider education defend margins. GeneSight: PGx leader as ~13% of US adults used antidepressants (2017–18); real-world evidence and payer wins drive adoption. Oncology CDx: $8.2B market (2024) with NGS profiling volumes +15% y\/y, creating durable partnered volume.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (2024)\u003c\/th\u003e\n\u003cth\u003eImplication\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGenetic-risk CAGR\u003c\/td\u003e\n\u003ctd\u003e~11%\u003c\/td\u003e\n\u003ctd\u003eHigh growth (Star)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAntidepressant use (US)\u003c\/td\u003e\n\u003ctd\u003e~13%\u003c\/td\u003e\n\u003ctd\u003ePGx demand for GeneSight\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompanion diagnostics\u003c\/td\u003e\n\u003ctd\u003e$8.2B\u003c\/td\u003e\n\u003ctd\u003eNGS-driven recurring revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eComprehensive BCG analysis of Myriad’s portfolio, identifying Stars, Cash Cows, Question Marks, and Dogs with strategic recommendations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page BCG snapshot pinpointing underperformers and growth bets—clarity for fast, confident portfolio decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy BRCA-focused testing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMature demand for legacy BRCA testing delivered steady volume in 2024, with payer coverage above 90% and durable reimbursement supporting reliable margins around 30–35%. Efficient, automated workflows kept cost per test low and promotional spend modest (\u0026lt;5% of test revenue). Prioritize further automation and keep guideline alignment current to protect volumes. Milk cash flows while cross-selling broader hereditary cancer panels to increase attach rates (≈10% uplift observed in 2024 pilots).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEstablished oncology panel volumes (repeat centers)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEstablished oncology panel volumes at repeat centers drive steady cash flow: by 2024 large health systems accounted for roughly 60% of institutional genomic panel orders, enabling routine ordering once clinical pathways are set. Low incremental selling cost and predictable reimbursement rates (Medicare\/Lab reimbursement stability in 2024) keep margins high. Protect volume with service SLAs and dedicated relationship management; small operational savings flow straight to margin.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProvider services: genetic counseling at scale\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eProvider services (genetic counseling) show stable utilization, routinely upselling adjacent tests and driving higher lifetime value per patient; sessions are incremental and high-margin. Infrastructure is largely built, so marginal cost per added telehealth session is low; keep staffing flexible and telehealth-first to preserve margins. Cash flow from counseling supports growth bets without heavy capex, funding R\u0026amp;D and commercial expansion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePayer-contracted test menu\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePayer-contracted test menu is a cash cow for Myriad: in-network status in 2024 reduced claim denials and administrative drag, preserving mature, profitable volume with low promotional spend and strong gross margins. Maintain coding accuracy and evidence dossiers to sustain reimbursement and compliance. Excess cash is being directed toward trials and market development to expand pipeline and payer coverage.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ein-network status (2024) lowers denials and admin costs\u003c\/li\u003e\n\u003cli\u003emature volumes, low promo spend, predictable margins\u003c\/li\u003e\n\u003cli\u003eprioritize coding accuracy and evidence dossiers\u003c\/li\u003e\n\u003cli\u003eexcess cash funds trials and market development\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLab operations and logistics backbone\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eLab operations and logistics backbone are high fixed-cost assets now operating at improved utilization, turning capital-intensive infrastructure into scalable margin drivers. Each additional sample meaningfully lifts contribution margin by spreading fixed costs across higher volumes. Continuous process improvement and automation steadily reduce cost per test, keeping the lab a quiet workhorse funding the R\u0026amp;D pipeline.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNASDAQ: MYGN — scalable lab platform\u003c\/li\u003e\n\u003cli\u003eHigh fixed-cost base now leveraged by volume\u003c\/li\u003e\n\u003cli\u003eProcess optimization lowers cost per test over time\u003c\/li\u003e\n\u003cli\u003eStable cash generation funds pipeline\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBRCA \u0026amp; oncology panels: \u0026gt;90% payer coverage, margins ~30–35%, promo \u0026lt;5%, attach +≈10%\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMature BRCA and oncology panels drove \u0026gt;90% payer coverage in 2024, margins ~30–35% and promo spend \u0026lt;5%; attach rates rose ≈10% in pilots and large systems supplied ~60% of institutional orders. Lab utilization and tele-counseling kept incremental cost low, freeing cash for trials and market dev.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayer coverage\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;90%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margin\u003c\/td\u003e\n\u003ctd\u003e30–35%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePromo spend\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAttach uplift\u003c\/td\u003e\n\u003ctd\u003e≈10%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview = Final Product\u003c\/span\u003e\u003cbr\u003eMyriad BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing here is the exact Myriad BCG Matrix report you'll receive after purchase. No watermarks, no placeholders—just a fully formatted, analysis-ready document. Once bought it lands in your inbox immediately and is editable, printable, and presentation-ready. Built by strategy pros for clarity and action, there are no surprises—what you see is what you get.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":56163366109561,"sku":"myriad-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/myriad-bcg-matrix.png?v=1762718543","url":"https:\/\/portersfiveforce.com\/products\/myriad-bcg-matrix","provider":"Porter's Five Forces","version":"1.0","type":"link"}